Steve Schonfeld’s Damora Therapeutics DMRA Stock Holding History

Steve Schonfeld’s Portfolio DMRA Stock Details DMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,824	Closed	-$280K	–	2756
2026 Q1	$280K	Buy	+10,824	New	+$278K	﹤0.01%	1600

Other funds holding DMRA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Jupiter Topco New York $245B AUM

RCP

Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

Steve Schonfeld's DMRA Position: Q2 2026 in Review

Steve Schonfeld sold out of Damora Therapeutics (DMRA) in Q2 2026, closing a stake of 10,824 shares — an estimated $280K sold.

Steve Schonfeld first reported a position in DMRA in Q1 2026 and held it in 1 quarter. The position peaked at $280K in Q1 2026. 103 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

Steve Schonfeld reported no remaining Damora Therapeutics position as of Q2 2026 after selling out during the quarter.
Steve Schonfeld sold 10,824 Damora Therapeutics shares in Q2 2026, an estimated $280K.
Steve Schonfeld first reported a position in Damora Therapeutics in Q1 2026 and held it in 1 quarter.
Steve Schonfeld's Damora Therapeutics position peaked at $280K in Q1 2026.
103 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.